| |
Prevalence of potential drug-drug interactions
with ritonavir-containing COVID-19 therapies
|
| |
| |
Presented at the 24th Annual MAD-ID Meeting; Orlando, FL, USA; May 18-21, 2022
Amy Puenpatom1; Marissa Grifasi Williams1; Yan Song2; Denise Yi2; Jessie Wang2; Miley Gu2; Chujun He2; Richard Berman2; and Ebuwa Igho-Osagie1
1Merck & Co., Inc., Rahway, NJ, USA; 2Analysis Group, Inc., Boston, MA, USA
|
|
| |
| |
|
|
|
